83.9 F
San Fernando
Wednesday, Apr 17, 2024

Court Rules in Amgen’s Favor in Patent Suit

Drug maker Amgen won an appeals court ruling Monday that prevents an Israeli company from seeking royalties on rheumatoid arthritis treatment Enbrel. Israel Bio-Engineering Project sued Thousand Oaks-based Amgen on charges the company violated Enbrel’s patent. But the L.A. U.S. District Court upheld a ruling that Yeda Research and Development Co., which licenses inventions of the Weizmann Institute of Science in Israel, owns a portion of the patent, thereby blocking the Israel Bio-Engineering Project suit. Enbrel generated $2.88 billion last year in North American sales.

Featured Articles

Related Articles